ONKO-INNATE

oNKo-innate is a discovery-stage biotechnology company dedicated to immuno-oncology target identification and therapeutic development. With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells... At oNKo-innate we believe that the next major advances in cancer immunotherapy will result from strategies that recruit, integrate and activate a more diverse immune response. With our leading understanding of Natural Killer ‘NK‘ cells as a key coordinator of efficient anti-tumour immunity, we are identifying and developing the next generation of cancer immunotherapies... Founded by Professor Nicholas Huntington (CSO) and Doctor Jai Rautela (CEO), oNKo-innate leverages a 20-year academic background in fundamental NK cell biology and cutting-edge in-house screening platforms to define and drug the dominant molecular mechanisms responsible for NK cell..

Also known as: oNKo-innate Pty. Ltd.

Registration numbers: 26 625 632 564 (W)

Primary location: Victoria Australia